secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042317
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q4 net income $49.9M, neffy sales $6.7M; pediatric approval expands market
--------------------------------------------------------------------------------

- neffy net product revenue $7.3M for FY2024 since Sep launch; Q4 net product revenue $6.7M.
- FDA approved neffy 1 mg for children 4+ and 15-30 kg on Mar 5, 2025; in pharmacies May 2025.
- Cash, equivalents & short-term investments $314M; operating runway at least 3 years.
- Payer coverage: >60% commercial lives under contract by end Q1 2025; >80% by early Q3.
- Phase 2b trial for chronic urticaria planned Q2 2025; topline data early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/0000950170-25-042317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer